Selinexor with standard therapies for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug called selinexor (KPT-330) combined with various standard treatments for patients whose multiple myeloma has come back or stopped responding to therapy. The goal is to see if adding selinexor helps control the cancer better than current options, and to find the safest dose for different drug pairings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have multiple myeloma that has returned or is no longer responding to treatment.
- You have measurable signs of myeloma in your blood or urine (like M-protein or free light chains).
- You are able to walk and take care of yourself (performance status score of 0 to 2).
- Your liver and kidney function tests meet specific levels depending on the drug combination you might receive.
- If you are a woman who can become pregnant, you must have a negative pregnancy test and agree to use effective birth control during and for 90 days after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs for people with multiple myeloma that has stopped responding to previous treatments. The goal is to see if adding selinexor to other anti-myeloma drugs can help control the disease.
This observational study looks at a three-drug combination (selinexor, bortezomib, and dexamethasone) for people with multiple myeloma that has come back after 1 to 3 prior treatments. It may be an option if you've already tried and not responded to lenalidomide.
This study tests whether taking selinexor after CAR-T cell therapy can help keep multiple myeloma from coming back. It is for people whose myeloma is high-risk or still has signs of disease after CAR-T.
This trial tests a medicine called SIL as a maintenance treatment for multiple myeloma. You take it after a stem cell transplant to help keep the cancer from coming back.
This trial tests a combination of four drugs (selinexor, carfilzomib, isatuximab, and dexamethasone) in patients whose multiple myeloma has come back or stopped responding to prior treatment. The goal is to see if this combination can shrink the cancer and help patients whose disease has high-risk features, like certain chromosome changes.
This trial tests a three-drug combination (selinexor, ruxolitinib, and methylprednisolone) for people with multiple myeloma that has come back or stopped responding after at least three prior treatments. The goal is to see if this new combination can help control the cancer.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.